2024-04-12 12:02:31 ET
Summary
- Altimmune is a clinical-stage biopharmaceutical company focused on developing peptide-based treatments for obesity and liver diseases.
- Their lead drug candidate, Pemvidutide, targets glucagon-like peptide-1 and glucagon receptors to produce weight loss with reduced side effects.
- Pemvidutide has shown promising results in clinical trials for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH), and the company is seeking partnerships for further development.
- ALT's strategic shift includes partnering discussions to enhance Pemvidutide's development pathway and potential commercialization.
- Overall I think ALT is a viable investment for investors who are aware of the inherent risks in biotech.
...
Read the full article on Seeking Alpha
For further details see:
Buy Altimmune's Potential market Disruption With Pemvidutide